6378 related articles for article (PubMed ID: 2822596)
1. Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390).
Peters GJ; Sharma SL; Laurensse E; Pinedo HM
Invest New Drugs; 1987; 5(3):235-44. PubMed ID: 2822596
[TBL] [Abstract][Full Text] [Related]
2. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Peters GJ; Schwartsmann G; Nadal JC; Laurensse EJ; van Groeningen CJ; van der Vijgh WJ; Pinedo HM
Cancer Res; 1990 Aug; 50(15):4644-9. PubMed ID: 2164443
[TBL] [Abstract][Full Text] [Related]
3. Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer.
Peters GJ; Nadal JC; Laurensse EJ; de Kant E; Pinedo HM
Biochem Pharmacol; 1990 Jan; 39(1):135-44. PubMed ID: 2153375
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis.
Chen SF; Ruben RL; Dexter DL
Cancer Res; 1986 Oct; 46(10):5014-9. PubMed ID: 3019518
[TBL] [Abstract][Full Text] [Related]
5. Differential susceptibility of dihydroorotate dehydrogenase/oxidase to Brequinar Sodium (NSC 368 390) in vitro.
Lakaschus G; Löffler M
Biochem Pharmacol; 1992 Mar; 43(5):1025-30. PubMed ID: 1313236
[TBL] [Abstract][Full Text] [Related]
6. DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects.
Schwartsmann G; Peters GJ; Laurensse E; de Waal FC; Loonen AH; Leyva A; Pinedo HM
Biochem Pharmacol; 1988 Sep; 37(17):3257-66. PubMed ID: 2840910
[TBL] [Abstract][Full Text] [Related]
7. The relation between inhibition of cell growth and of dihydroorotic acid dehydrogenase by brequinar sodium.
de Kant E; Pinedo HM; Laurensse E; Peters GJ
Cancer Lett; 1989 Jul; 46(2):123-7. PubMed ID: 2546667
[TBL] [Abstract][Full Text] [Related]
8. Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(12):666-678. PubMed ID: 30663496
[TBL] [Abstract][Full Text] [Related]
9. Effect of 6-azauridine on de novo pyrimidine biosynthesis in cultured Ehrlich ascites cells. Orotate inhibition of dihydroorotase and dihydroorotate dehydrogenase.
Chen JJ; Jones ME
J Biol Chem; 1979 Jun; 254(11):4908-14. PubMed ID: 35542
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.
Cleaveland ES; Zaharevitz DW; Kelley JA; Paull K; Cooney DA; Ford H
Biochem Biophys Res Commun; 1996 Jun; 223(3):654-9. PubMed ID: 8687451
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
Chen SF; Perrella FW; Behrens DL; Papp LM
Cancer Res; 1992 Jul; 52(13):3521-7. PubMed ID: 1617622
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic effects of inhibitors of de novo pyrimidine biosynthesis upon Plasmodium falciparum.
Seymour KK; Lyons SD; Phillips L; Rieckmann KH; Christopherson RI
Biochemistry; 1994 May; 33(17):5268-74. PubMed ID: 7909690
[TBL] [Abstract][Full Text] [Related]
13. Uridine and cytidine metabolism following inhibition of de novo pyrimidine synthesis by pyrazofurin.
Cadman E; Benz C
Biochim Biophys Acta; 1980 Oct; 609(3):372-82. PubMed ID: 7437431
[TBL] [Abstract][Full Text] [Related]
14. Dual effects of pyrazofurin and 3-deazauridine upon pyrimidine and purine biosynthesis in mouse L1210 leukemia.
Sant ME; Lyons SD; Kemp AJ; McClure LK; Szabados E; Christopherson RI
Cancer Res; 1989 May; 49(10):2645-50. PubMed ID: 2713848
[TBL] [Abstract][Full Text] [Related]
15. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(6):329-339. PubMed ID: 29723133
[TBL] [Abstract][Full Text] [Related]
16. Cellular pharmacology of DUP-785, a new anticancer agent.
Anderson LW; Strong JM; Cysyk RL
Cancer Commun; 1989; 1(6):381-7. PubMed ID: 2562006
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors.
DeFrees SA; Sawick DP; Cunningham B; Heinstein PF; Morré DJ; Cassady JM
Biochem Pharmacol; 1988 Oct; 37(20):3807-16. PubMed ID: 2847745
[TBL] [Abstract][Full Text] [Related]
18. Enzymes of de novo pyrimidine biosynthesis in Babesia rodhaini.
Holland JW; Gero AM; O'Sullivan WJ
J Protozool; 1983 Feb; 30(1):36-40. PubMed ID: 6134826
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine.
Peters GJ; Kraal I; Pinedo HM
Br J Cancer; 1992 Feb; 65(2):229-33. PubMed ID: 1739622
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
